FIG 6.

Quantitative effects of stilbenoids on infectious SARS-CoV-2 replication in vitro. (A) Dose-response curve of REGN10933 on cell viability in infected Vero-E6 cells after 4 days of infection with 150× TCID₅₀ of SARS-CoV-2 (USA-WA1/2020 variant). (B) Dose-response curve of stilbenoids, resveratrol, and remdesivir on cell viability in infected Vero-E6 cells. The gray dotted lines in panels A and B indicate infected cell viability plus 0.1% DMSO vehicle control. Results in panels A and B represent the mean ± SEM from 3 independent experiments. (C) Representative images of Vero-E6 cells treated with 1:10 dilutions of supernatants from CPE scoring-based assays. Blue denotes Hoechst-stained cell nuclei, and red indicates SARS-CoV-2 nucleocapsid-positive infected cells. Scale bar = 50 μm. (D) Dose-response curve of REGN10933 on nucleocapsid-positive cells following supernatant treatments from CPE-scoring based assays. (E) Dose-response curves of stilbenoids and remdesivir on nucleocapsid-positive cells following supernatant treatments from CPE-scoring based assays. Dotted lines in panels D and E denote the percentage of nucleocapsid-positive cells following treatment with infected supernatants plus 0.1% DMSO. Results in panels D and E represent the mean ± SD from two independent experiments.